A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA1), UCM-05194, Shows Efficacy in Neuropathic Pain Amelioration
- 16 December 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (5) , 2372-2390
Abstract
Neuropathic pain (NP) is a complex chronic pain state with a prevalence of almost 10% in the general population. Pharmacological options for NP are limited and slightly effective, so there is a need of developing more efficacious NP attenuating drugs. Activation of the type 1 lysophosphatidic acid (LPA1) receptor is a crucial factor in the initiation of NP. Hence, it is conceivable that a functional antagonism strategy could lead to NP mitigation. Here we describe a new series of LPA1 agonists among which derivative (S)-17 (UCM-05194) stands out as the most potent and selective LPA1 receptor agonist described so far (Emax=118%, EC50=0.24 µM, KD=19.6 nM; inactive at autotaxin and LPA2-6 receptors). This compound induces characteristic LPA1-mediated cellular effects and prompts the internalization of the receptor leading to its functional inactivation in primary sensory neurons and to an efficacious attenuation of the pain perception in an in vivo model of NP.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (NS084398)
- European Regional Development Fund (PI16/01698)
- Ministerio de Econom?a y Competitividad (RTI2018-097189-B-C21, SAF2015-66275-C2-1, SAF2016-78792-R, SAF2016-79774-R)
- Instituto de Salud Carlos III
- Sociedad Espa?ola de Qu?mica Terap?utica
- Red De Terapia Celular
- Wings for Life international foundation
This publication has 59 references indexed in Scilit:
- Regulation of tumor cell – Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axisAdvances in Biological Regulation, 2019
- Bioactive lysolipids in cancer and angiogenesisPharmacology & Therapeutics, 2019
- Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging TargetsJournal of Medicinal Chemistry, 2016
- Lysophosphatidic acid receptor (LPAR) modulators: The current pharmacological toolboxProgress in Lipid Research, 2015
- Lysophosphatidic Acid Signaling in the Nervous SystemNeuron, 2015
- Lysophospholipid receptor nomenclature review: IUPHAR Review 8British Journal of Pharmacology, 2014
- LPA receptor signaling: pharmacology, physiology, and pathophysiologyJournal of Lipid Research, 2014
- Insights into the pharmacological relevance of lysophospholipid receptorsBritish Journal of Pharmacology, 2012
- Regulation of Mammalian Physiology, Development, and Disease by the Sphingosine 1-Phosphate and Lysophosphatidic Acid ReceptorsChemical Reviews, 2011
- LPA Receptors: Subtypes and Biological ActionsAnnual Review of Pharmacology and Toxicology, 2010